Epidemiological studies indicate that patients with a history using non-steroidal anti-inflammatory drugs (NSAID, COX1/2 inhibitor, and PPARγ agonist) have decreased risk for neurodegeneration, such as AD (Fig. 2). This evidence concerns the gene PPARG and Alzheimer disease.